Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Clinical Lymphoma, Myeloma & Leukemia|June 5, 2024
Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor TherapyShivani Handa, Ganesh Sivakumar, Andrew Srisuwananukorn, et al.
Blood|July 11, 2025
Thrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expressionLilian Varricchio, Gohar Mosoyan, Sebastian El Ghaity-Beckley, et al.
Blood Advances|December 15, 2022
Obstetric and perioperative management of patients with factor XI deficiency: a retrospective observational studyShivani Handa, Michelle Sterpi, Guilherme Sacchi De Camargo Correia, et al.
The Oncologist|October 30, 2025
Examining inpatient chemotherapy utilization among patients with cancer and impact on outcomesGiulia Petrone, Shivani Handa, Justine Anderson, et al.
Leukemia|December 23, 2024
HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosisShivani Handa, Christoph Schaniel, Joseph Tripodi, et al.
JCO Precision Oncology|January 31, 2024
Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic InsightsShivani Handa, Kyle A Farina, Michelle Becker, et al.
Cancers|January 10, 2026
Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation TrialShivani Handa, Kristin Koenig, Qiuhong Zhao, et al.
Blood|August 5, 2022
Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapyShivani Handa, Jeong-Ok Lee, Andriy Derkach, et al.
Blood Neoplasia|January 5, 2026
Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AMLJayanshu Jain, Kelly Pugh, Shivani Handa, et al.
Haematologica|April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study resultsMichael J Hochman, Amy S Ruppert, Ying Huang, et al.
Pageof 3